13.05.2024 – 14:59
BPI Federal Association of the Pharmaceutical Industry
Berlin (ots)
Around 40 percent of Germans have already had experience with drug delivery bottlenecks – a clear majority is calling for more support from politicians for domestic drug manufacturers:
Around half of those surveyed are concerned that in five years there will be significantly fewer drug manufacturers in Germany than there are today, better framework conditions are required for pharmaceutical companies active in this country in research and production, 72 percent of those surveyed feel that drug prices are too high – bureaucracy is a key cost driver .
Delivery bottlenecks in the supply of medicines are also a reality in the highly industrialized country of Germany: 41 percent of Germans have already had personal experience with drug delivery bottlenecks. The representative “Germany as a pharmaceutical location” survey by the opinion research institute INSA-CONSULERE on behalf of the Federal Association of the Pharmaceutical Industry (BPI) from May 2024 shows that a strong domestic pharmaceutical industry is viewed as central to the security of supply of medicines. In the opinion of those surveyed, the basis for this is primarily an improvement of the existing legal framework by politicians. 51 percent of participants are worried that the number of drug manufacturers in Germany will fall significantly in the next five years.
An absolute majority of 81 percent therefore demands that Germany must become more independent of global supply chains. Likewise, 82 percent of those surveyed are of the opinion that the federal government must create better framework conditions for the establishment of pharmaceutical companies as well as for pharmaceutical research and production in Germany. The federal government should protect pharmaceutical companies operating in this country and thus Germany as a pharmaceutical location as a whole more strongly than before, for example against insolvencies and emigration (76 percent).
Those surveyed also criticize the high medication costs, which 72 percent consider to be too high, as well as the excessive bureaucracy in the health system, which, according to 77 percent of the participants, contributes to increasing costs.
Dr. Kai Joachimsen, General Manager of the BPI, emphasizes the urgency of the situation: “Delivery bottlenecks not only pose a threat to health care, but also to Germany as a business location, to progress, prosperity and jobs. It is high time for politicians to act and join in “We don’t need subsidies to develop sustainable solutions in the pharmaceutical industry, but we do need a framework in which we can research, develop and produce adequately.”
For the representative survey, 1,003 people in Germany aged 18 and over were surveyed online by the market research institute INSA-CONSULERE between May 3 and May 6, 2024. The survey is based on the permanent telephone survey INSA-Perpetua Demoscopia.
Here you can find all the results of the INSA survey “Germany as a pharmaceutical location”.
Press spokesman:
Andreas Aumann
Tel. 030 27909-123
[email protected]
Original content from: BPI Federal Association of the Pharmaceutical Industry, transmitted by news aktuell